{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:40:06Z","timestamp":1786992006088,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,4,19]],"date-time":"2017-04-19T00:00:00Z","timestamp":1492560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jdiacomp.2017.03.012","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T02:18:41Z","timestamp":1490840321000},"page":"1181-1187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy"],"prefix":"10.1016","volume":"31","author":[{"given":"Dan","family":"Ziegler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Edmundson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Gurieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Mankovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6950-7166","authenticated-orcid":false,"given":"Igor","family":"Strokov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0022-510X(01)00584-6","article-title":"Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials","volume":"189","author":"Apfel","year":"2001","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1464-5491.1994.tb00223.x","article-title":"A prospective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy","volume":"11","author":"Benbow","year":"1994","journal-title":"Diabet Med"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/qjmed\/91.11.733","article-title":"Diabetic peripheral neuropathy and quality of life","volume":"91","author":"Benbow","year":"1998","journal-title":"QJM"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0020","doi-asserted-by":"crossref","first-page":"e74195","DOI":"10.1371\/journal.pone.0074195","article-title":"Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study","volume":"8","author":"Bouhassira","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0025","first-page":"S1038","article-title":"Current and emerging treatments for diabetic peripheral neuropathy","volume":"5","author":"Boulton","year":"2005","journal-title":"Adv Stud Med"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/dmrr.2397","article-title":"Whither pathogenetic treatments for diabetic polyneuropathy?","volume":"29","author":"Boulton","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0035","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.2337\/diacare.27.6.1458","article-title":"Diabetic somatic neuropathies","volume":"27","author":"Boulton","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10354-011-0865-y","article-title":"Actovegin(R): a biological drug for more than 5 decades","volume":"161","author":"Buchmayer","year":"2011","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0045","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.2337\/diacare.26.5.1589","article-title":"New insights on oxidative stress and diabetic complications may lead to a \"causal\" antioxidant therapy","volume":"26","author":"Ceriello","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0050","first-page":"CD004572","article-title":"Aldose reductase inhibitors for the treatment of diabetic polyneuropathy","volume":"4","author":"Chalk","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0055","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1007\/s00125-006-0380-7","article-title":"The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy","volume":"49","author":"Currie","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J Pain"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0065","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1212\/WNL.49.1.229","article-title":"Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester diabetic neuropathy study cohort","volume":"49","author":"Dyck","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0070","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12017-011-8157-7","article-title":"Neuroprotective and anti-oxidative effects of the hemodialysate actovegin on primary rat neurons in vitro","volume":"13","author":"Elmlinger","year":"2011","journal-title":"NeuroMolecular Med"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0075","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0080","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study","volume":"342","author":"Gress","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0085","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.2174\/13816128113196660673","article-title":"The role of statins in the treatment of type 2 diabetes mellitus: an update","volume":"20","author":"Katsiki","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0090","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2337\/dc09-0749","article-title":"Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly west award lecture 2008","volume":"33","author":"Laakso","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0095","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0100","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/S0140-6736(98)02478-7","article-title":"Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial","volume":"352","author":"Malik","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0105","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ejp.763","article-title":"Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?","volume":"20","author":"Marchettini","year":"2016","journal-title":"Eur J Pain"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0110","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.2337\/dc10-0616","article-title":"Vibration perception threshold as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the DCCT\/EDIC study","volume":"33","author":"Martin","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0115","first-page":"234","article-title":"Health-related quality of life in patients with diabetic foot problems in Malaysia","volume":"66","author":"Mazlina","year":"2011","journal-title":"Med J Malays"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00005650-199401000-00004","article-title":"The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups","volume":"32","author":"McHorney","year":"1994","journal-title":"Med Care"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0125","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1111\/jcmm.12297","article-title":"Treatment with actovegin improves spatial learning and memory in rats following transient forebrain ischaemia","volume":"18","author":"Meilin","year":"2014","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1756-0500-5-52","article-title":"Meta-analyses and forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis","volume":"5","author":"Neyeloff","year":"2012","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0135","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1464-5491.2002.00706.x","article-title":"A comparison of the Neuropen against standard quantitative sensory-threshold measures for assessing peripheral nerve function","volume":"19","author":"Paisley","year":"2002","journal-title":"Diabet Med"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0140","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1517\/14656566.2014.972935","article-title":"Efficacy of alpha-lipoic acid in diabetic neuropathy","volume":"15","author":"Papanas","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0145","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1799","article-title":"Painful diabetic neuropathy","volume":"348","author":"Peltier","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0150","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ana.410380323","article-title":"Diabetic polyneuropathy in controlled clinical trials: consensus report of the peripheral nerve society","volume":"38","author":"Peripheral Nerve Society","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0155","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/HYPERTENSIONAHA.111.174474","article-title":"Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial","volume":"58","author":"Ruggenenti","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0160","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","article-title":"Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes","volume":"61","author":"Schrier","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0165","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.2337\/dc07-1103","article-title":"Glycemic effects of moderate alcohol intake among patients with type 2 diabetes: a multicenter, randomized, clinical intervention trial","volume":"30","author":"Shai","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0170","doi-asserted-by":"crossref","first-page":"e103280","DOI":"10.1371\/journal.pone.0103280","article-title":"Simulating the impact of improved cardiovascular risk interventions on clinical and economic outcomes in Russia","volume":"9","author":"Shum","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0175","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/dc15-2068","article-title":"Long-acting C-peptide and neuropathy in type 1 diabetes: a 12-month clinical trial","volume":"39","author":"Wahren","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0180","doi-asserted-by":"crossref","DOI":"10.2337\/dc15-2068","article-title":"Long-acting C-peptide and neuropathy in type 1 diabetes: a 12-month clinical trial","author":"Wahren","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0185","author":"Weng"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0190","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2337\/diacare.17.6.557","article-title":"The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study","volume":"17","author":"Young","year":"1994","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0195","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/BF00400603","article-title":"Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN study)","volume":"38","author":"Ziegler","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0200","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jdiacomp.2015.10.018","article-title":"Predictors of improvement and progression of diabetic polyneuropathy following treatment with alpha-lipoic acid for 4years in the NATHAN 1 trial","volume":"30","author":"Ziegler","year":"2016","journal-title":"J Diabetes Complicat"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0205","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.2337\/dc11-0503","article-title":"Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial","volume":"34","author":"Ziegler","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0210","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2337\/dc09-0545","article-title":"Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients","volume":"32","author":"Ziegler","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/B978-0-444-53480-4.00001-1","article-title":"Epidemiology of polyneuropathy in diabetes and prediabetes","volume":"126","author":"Ziegler","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.jdiacomp.2017.03.012_bb0220","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2337\/dc06-2009","article-title":"Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain","volume":"30","author":"Ziegler","year":"2007","journal-title":"Diabetes Care"}],"updated-by":[{"DOI":"10.1016\/j.jdiacomp.2017.08.008","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000}}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716305086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716305086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:07:15Z","timestamp":1761005235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872716305086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1056872716305086"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.03.012","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}